Clinical efficacy and safety of istradefylline in the treatment of advanced Parkinson's disease: a retrospective study

Clinical efficacy and safety of istradefylline in the treatment of advanced Parkinson's disease: a retrospective study - Clinical efficacy and safety of istradefylline in the treatment of advanced Parkinson's disease: a retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020562

Enrollment

Registered

2016-01-14

Start date

2015-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?Patients who received istradefylline in the period from May 2013 to May 2015 ?Parkinson's disease patients having wearing-off phenomenon under treatment with medications containing levodopa ?Outpatient

Exclusion criteria

Exclusion criteria: ?Patients who have moderate or severer hepatic disorder or are receiving strong CYP3A4 inhibitors. ?Women who are lactating or pregnant or are suspected of being pregnant.

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression-Improvement(CGI-I) Improvement for each motor symptom	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactYasuto Higashi

Himeji Central Hospital Neurology

yasuto@mvj.biglobe.ne.jp079-235-7331

Outcome results